CN116536235A - Bacillus subtilis for efficiently secreting and expressing osteopontin as well as construction method and application thereof - Google Patents

Bacillus subtilis for efficiently secreting and expressing osteopontin as well as construction method and application thereof Download PDF

Info

Publication number
CN116536235A
CN116536235A CN202310592888.1A CN202310592888A CN116536235A CN 116536235 A CN116536235 A CN 116536235A CN 202310592888 A CN202310592888 A CN 202310592888A CN 116536235 A CN116536235 A CN 116536235A
Authority
CN
China
Prior art keywords
bacillus subtilis
opn
expression
osteopontin
rbs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202310592888.1A
Other languages
Chinese (zh)
Inventor
吕雪芹
刘龙
陈坚
堵国成
刘元法
李江华
李洋
张予婷
武耀康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baima Future Food Research Institute
Jiangnan University
Original Assignee
Baima Future Food Research Institute
Jiangnan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baima Future Food Research Institute, Jiangnan University filed Critical Baima Future Food Research Institute
Priority to CN202310592888.1A priority Critical patent/CN116536235A/en
Publication of CN116536235A publication Critical patent/CN116536235A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus
    • C12R2001/125—Bacillus subtilis ; Hay bacillus; Grass bacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention discloses bacillus subtilis capable of efficiently secreting and expressing osteopontin, a construction method and application thereof. In the strain, the expression of the protein is enhanced by a strong promoter P21, and then the RBS-signal peptide combination suitable for the secretory expression of the OPN is screened by a SCORE method, so that the secretory expression of the OPN is successfully realized, wherein the total OPN protein yield of the OPN4 of the recombinant B.subilis strain with the highest secretory quantity is 126.32 mu g l ‑1 The amount of secreted protein was 33.32. Mu. g l ‑1 . The humanized OPN produced by the recombinant bacteria constructed by the invention has stable expression, high expression quantity and wide application rangeBroad application prospect.

Description

Bacillus subtilis for efficiently secreting and expressing osteopontin as well as construction method and application thereof
Technical Field
The invention relates to bacillus subtilis for efficiently secreting and expressing osteopontin, and a construction method and application thereof, and belongs to the technical field of metabolic engineering.
Background
Osteopontin (OPN) is a negatively charged, hyperphosphorylated and glycosylated protein with an isoelectric point of 3.6.OPN contains an RGD (arginine-glycine-aspartic acid, arg-Gly-Asp) sequence, which can bind to integrin receptors on cell surfaces and participate in cell adhesion, migration and signal transduction. Osteopontin was originally found in osteoblasts and is an important component of the extracellular matrix involved in bone formation, remodeling and mineralization. In addition to expression in bone, osteopontin is also expressed in a variety of other tissues and cells, such as tubular epithelial cells, macrophages, lymphocytes, tumor cells, and the like. In recent years, OPN has been found to be a very important class of immunologically active proteins in breast milk, particularly colostrum, where the OPN content is very high. The OPN accounting for 5% -10% of the total protein content of the breast milk which is taken as the optimal source of the energy, the nutrient and the bioactive components of the infant has important significance for the maturation of the immune system, the intestinal development and the cognitive development of the infant. And the OPN can make the formula milk powder simulate the breast milk component, and provide nutrition and protection similar to that of breast milk for infants.
Currently, osteopontin is mainly produced by extracting and purifying osteopontin from cow's milk or human milk, and separating OPN from cow's whey using anion exchange technology, wherein the final product contains about 78% protein, 95% of which is OPN. OPN (Lacprodan OPN-10) isolated by this method contains ash (up to 9%), moisture (up to 5%) and less than 1% fat and lactose. The Lacprodan OPN-10 is the only OPN finished product sold in the market at present. However, the amount of OPN in cow's milk was extremely low, and about 11mg of OPN was extracted from 1L of raw milk, and about 90 tons of OPN was extracted from cow's milk, based on the amount of OPN extracted. Thus, large-scale marketability of OPN is difficult to achieve by fresh milk extraction, which may lead to denaturation or inactivation of proteins, and is costly. Under the drive of leading-edge biotechnology such as gene editing, synthetic biology, whole genome selection and the like, the industrial fermented milk proteins (such as whey proteins and casein) of microbial cells and corresponding nutritional components are designed and modified, and the realization of accurate nutrition and green production of artificial dairy products is an optimal method for solving the contradiction between the growing dairy product demands and the certain defects of natural dairy products. Heterologous expression of OPN by taking Pichia pastoris as a host is studied at present, and higher yield is achieved, but pichia pastoris fermentation takes methanol as a carbon source, methanol metabolism can generate byproducts such as formaldehyde and formic acid, and the byproducts can have negative influence on growth and metabolism of Pichia pastoris; moreover, methanol is a toxic chemical substance, and has potential safety hazard; in addition, pichia pastoris requires a long time for methanol metabolism, so that a long culture time is required, fermentation is generally about 7 days, and cost is high.
Bacillus subtilis (Bacillus subtilis) has a clear genetic background and mature genetic manipulation technology and has therefore been used as a model microorganism for studying gram-positive bacteria; the strain has the excellent characteristics of high growth rate, strong secretion capacity, no obvious codon preference, low susceptibility to phage infection and the like, and is also a production strain commonly used in industrial fermentation; in addition, since harmful products such as endotoxin are not produced, b.subilis is also certified by the U.S. food and drug safety administration (FDA) as strain GRAS (Generally recognized as safe), and is a well-known food-safe microorganism that secretes OPN as an expression host. However, the human OPN is used as a foreign protein from eukaryotic sources, and has the problems of difficult expression, low expression level, difficult secretion and the like in a bacterial protein expression system.
Disclosure of Invention
In order to solve the problems, the invention successfully constructs the OPN expression strain, successfully secretes and expresses the OPN through the combination screening of a Ribosome Binding Site (RBS) and a signal peptide, effectively avoids the accumulation of the protein in cells, and simplifies the subsequent separation and purification process, thereby reducing the cost of the production process and being expected to be used for the subsequent large-scale fermentation production.
The first object of the invention is to provide a bacillus subtilis for efficiently secreting and expressing osteopontin, which takes pHT-01 as a carrier and P21 as a promoter to heterologously express human osteopontin.
Further, the amino acid sequence of the human osteopontin is shown as SEQ ID NO. 2.
Further, the nucleotide sequence of the P21 promoter is shown as SEQ ID NO. 3.
Further, the bacillus subtilis also comprises the step of promoting the secretion expression of human osteopontin by RBS and signal peptide.
Further, the RBS is selected from one of the nucleotide sequences shown in SEQ ID NO. 6-23.
Further, the signal peptide is selected from the group consisting of SP YlxW 、SP YwmC 、SP YhdC 、SP YybN 、SP YnfF 、SP YwtD 、SP SpollR 、SP MotB 、SP YxiT 、SP YurL 、SP LytB 、SP Vpr 、SP YbbE 、SP LipA 、SP YddT 、SP Ymol 、SP BdbD One of them.
Further, in the bacillus subtilis, the expression plasmid is pHT-P21-RBS1-SP YwmC -OPN、pHT-P21-RBS2-SP YurL -OPN or pHT-P21-RBS3-SP BdbD OPN, wherein the nucleotide sequence of RBS1 is as followsSEQ ID NO.7 shows the nucleotide sequence of RBS2 as SEQ ID NO.15 and RBS3 as SEQ ID NO. 23.
Further, the host of the bacillus subtilis is B.subtilis G601. The strain is disclosed in the patent publication No. CN113957028A, has simple and convenient transformation, no nutritional defect, better amino acid utilization capability and capability of effectively improving the capability of producing protein by reducing the metabolic pressure of cells by knocking out 6 extracellular protease genes of a wild B.subtilis 168 strain.
Further, the bacillus subtilis also includes a fusion of a 6×his tag at the C-terminus of the human osteopontin. Which can be used in subsequent separation and purification processes.
The second object of the invention is to provide a construction method of the bacillus subtilis, comprising the following steps:
s1, constructing a P21 promoter, a coding gene of a human osteopontin and an expression element on a pHT-01 vector to obtain an expression vector;
s2, converting the expression vector into a bacillus subtilis host, and screening to obtain the bacillus subtilis.
The third object of the invention is to provide the application of the bacillus subtilis in the fermentation production of human osteopontin.
Further, the application is that the seed solution of the bacillus subtilis is inoculated into a fermentation culture medium according to the inoculation amount of 2-5 percent by volume, and is cultured for 12-96 hours under the conditions of 35-37 ℃ and 200-220 rpm.
Further, the fermentation medium comprises 10-15 g/L peptone, 20-30 g/L yeast powder, 8-12 g/L NaCl, 2-5 mL/L glycerol and KH 2 PO 4 2.0～2.5g/L，K 2 HPO 4 12～13g/L。
The beneficial effects of the invention are as follows:
the invention firstly constructs recombinant B.subilis strain OPN1 which can successfully express human OPN, uses the recombinant B.subilis strain OPN1 to ferment and uses ELISA to verify that the expression can be successfully detected, and the total yield is 97.44 mu g l -1 . In this strain, the eggs are reinforced by a strong promoter P21White expression, screening out signal peptide-RBS combination suitable for OPN secretion expression by SCORE method, and successfully implementing OPN secretion expression, wherein recombinant B.subilis strain OPN4 with highest secretion amount (expression plasmid is pHT-P21-RBS 3-SP) BdbD Total OPN protein yield of-OPN) was 126.32. Mu. g l -1 The amount of secreted protein was 33.32. Mu. g l -1 . The humanized OPN produced by the recombinant bacteria constructed by the invention has stable expression and high expression quantity, and has wide application prospect.
Description of the drawings:
FIG. 1 is a schematic diagram of recombinant expression plasmid construction;
FIG. 2 is a schematic diagram of a combination optimized RBS and signal peptide;
FIG. 3 standard ELISA assay curves for osteopontin;
figure 4 osteopontin yield.
Detailed Description
The present invention will be further described with reference to specific examples, which are not intended to be limiting, so that those skilled in the art will better understand the present invention and practice it.
Strain and vector:
plasmid construction was performed in E.coli DH 5. Alpha. And the plasmid construction was transformed into B.subtilis G601 for OPN expression and fermentation. The vector pHT-01 used was a commercial plasmid.
(II) culture medium:
both the subtitle seeds and E.coli were cultivated using LB medium (10 g tryptone, 5g yeast powder and 10g NaCl per liter). The engineering strain is fermented by using TB culture medium (12 g tryptone, 24g yeast powder, 10g NaCl and 2.31g KH per liter) 2 PO 4 、12.54g K 2 HPO and 4mL glycerol).
Example 1: construction of OPN recombinant expression plasmid pHT-P21-OPN
As shown in FIG. 1, the human osteopontin OPN expression cassette constructed is composed of OPN gene and 6 XHis tag 2 part. The Genbank accession number of OPN is np_001035147.1, which has been optimized according to the codon preference of b.subtilis, and the nucleotide sequence and amino acid sequence thereof are shown in SEQ ID No.1 and SEQ ID No.2, respectively. The nucleotide sequence of the promoter P21 is shown as SEQ ID NO. 3. The nucleotide sequence and the amino acid sequence of the 6 XHis tag are shown as SEQ ID NO.4 and SEQ ID NO.5 respectively, and recombinant proteins can be purified by using a nickel column through the tag.
In order to enhance the expression of OPN in B.subtilis, the expression vector used is a commercial plasmid pHT-01 vector which is a vector for stably expressing protein, and the invention uses sigma in B.subtilis H The promoter P21 (the nucleotide sequence is shown as SEQ ID NO. 3) identified by the factor expresses OPN, and the promoter cannot be expressed in E.coli, so that the smooth construction of recombinant expression plasmids can be ensured. High-intensity expression can be sustained in the b.subtills. After P21 was ligated together with the synthesized gene element to vector pHT-01, vector pHT-P21-OPN was obtained. After the plasmid was transformed into the B.subtilis G601 strain, an engineering strain OPN1 capable of efficiently expressing OPN was obtained.
Example 2: construction of OPN secretory expression plasmid
The SCORE method was used to screen RBS-signal peptide combinations suitable for secretory expression of OPN. The construction method, primer design, verification primer design and screening methods of a specific plasmid of this method are described in A genetic toolkit for efficie nt production of secretory protein in Bacillus subtilis. The principle of the method is that green fluorescent protein superfolder green fluorescent protei n (sfGFP) is fused after OPN protein, and the secretion amount of OPN is characterized by the fluorescence intensity in the supernatant of fermentation broth. The mixing system of Golden gate and its PCR method before RBS library and signal peptide library were ligated to fusion proteins by Golden gate are shown in tables 1 and 2. The library of signal peptides screened is composed of 173 signal peptides of the Sec secretion pathway endogenous to bacillus subtilis and of 16 RBS libraries with different translational strengths, the size of the library contained is 173×16=2768 combinations. The method operates as follows (fig. 2):
1. connecting an OPN protein sequence to a screening plasmid to obtain a template plasmid pHT-P21-RBS-SP-OPN-sfGFP, wherein the plasmid consists of a promoter P21, two Eco 31I cleavage sites and OPN-sfGFP fusion protein;
2. constructing an RBS library, using RBS (AAGGAGATATACC) as an initial RBS, using degenerate primers RBS-F and RBS-R, adding an Eco 31I cleavage site at both ends and obtaining an RBS mixed library (MAGGMRGWATCAC), which library contains 16 RBSs with different transcription intensities;
3. constructing a signal peptide combinatorial library, downloading 173 sec-pathway signal peptides of B.subtilis in a Signal Sequence Database database, designing primers, adding an Eco 31I cleavage site at two ends of a signal peptide fragment, amplifying the fragment from a genome, and mixing to obtain the signal peptide library;
4. the template plasmid pHT-P21-RBS-SP-OPN-sfGFP, RBS library and signal peptide library were ligated using the Golden gate method, and the mixing system and PCR procedure were as follows.
TABLE 1Golden gate connection System
Eco31I endonuclease 1.5μL
T4 ligase 3μL
10×T4 buffer 1.5μL
Template plasmid 75ng
RBS library 25ng
Signal peptide library 25ng
ddH 2 O Added to 15 mu L
TABLE 2 reaction conditions
5. Transforming the constructed connecting vector into escherichia coli, cloning to obtain a mixed plasmid, transferring the mixed plasmid into bacillus subtilis G601, picking the mixed plasmid into a 96-well plate for fermentation verification, centrifuging at 4000rpm for 5 min by using a well plate centrifuge after 24h, sucking out supernatant, and measuring fluorescence intensity in the supernatant;
6. the fluorescence intensities of the supernatants varied from 500-2000, from which we selected 18 Bacillus subtilis extract plasmids with different fluorescence expression intensities, which were sequenced to obtain 18 fusion protein expression plasmids with different RBS-signal peptide combinations, the RBS sequences and the nucleotide sequences of the signal peptides of which are shown in Table 3. From which 2,10,18 three plasmids were selected, pHT-P21-RBS1-SP, respectively YwmC -OPN-sfGFP、pHT-P21-RBS2-SP YurL OPN-sfGFP and pHT-P21-RBS3-SP BdbD OPN-sfGFP was used for subsequent fermentation verification.
TABLE 3 Table 3
7. The sfGFP gene sequences of the three plasmid vectors are removed by PCR to obtain the OPN secretory expression vector pHT-P21-RBS1-SP YwmC -OPN、pHT-P21-RBS2-SP YurL OPN and pHT-P21-RBS3-SP BdbD OPN. Signal peptide SP YwmC 、SP YurL And SP BdbD The nucleotide sequence and the amino acid sequence of the polypeptide are shown as SEQ ID NO.24-26 and SEQ ID NO.27-29 respectively. After the plasmid is transformed into the B.subtilis G601 strain, the engineering strain OPN2-4 capable of efficiently expressing OP N is obtained.
Example 3: efficient expression of OPN in recombinant strains
The engineering strains OPN1-4 obtained in example 1 and example 2 were inoculated into a seed medium containing chloramphenicol (5 mg/L) at 37℃and 220rpm for shake culture overnight. Then, the cells were transferred to a fermentation medium containing chloramphenicol (5 mg/L) at an inoculum size (v/v) of 4% and cultured with shaking at 37℃and 220rpm for 12-96 hours.
Example 4: protein production assay for OPN
The standard of osteopontin was diluted in gradient to a concentration of 0, 50, 100, 200, 400, 800ng/L, respectively, using human osteopontin ELISA kit, and co-detected with the samples to finally obtain absorbance as shown in table 4, and a regression curve was made as shown in fig. 3, fitting equation of which was y=0.001422 x+0.06002, where x is OPN protein concentration (ng/L) and y is absorbance.
Table 4 detection of absorbance by standard
Standard substance concentration (ng/L) 0 31.25 52.5 125 250 500 1000 2000
Absorbance (OD) 450 ) 0.021 0.124 0.104 0.2 0.433 0.807 1.595 2.84
The fermentation sample for 24 hours and 1 negative control were taken and diluted in a gradient of 100-fold each, and the samples were subjected to parallel detection, and the results are shown in Table 5 and FIG. 4.
TABLE 5OPN protein yield
Strain Supernatant of fermentation broth (mu g l) -1 ) Cell pellet (mu g l) -1 ) Total content (mu g l) -1 )
G601 1.08 0.8 1.88
OPN-1 1.12 96.32 97.44
OPN-2 8.79 87.24 96.13
OPN-3 21.75 85.23 106.98
OPN-4 33.32 93 126.32
The above-described embodiments are merely preferred embodiments for fully explaining the present invention, and the scope of the present invention is not limited thereto. Equivalent substitutions and modifications will occur to those skilled in the art based on the present invention, and are intended to be within the scope of the present invention. The protection scope of the invention is subject to the claims.

Claims (10)

1. The bacillus subtilis for efficiently secreting and expressing the osteopontin is characterized by taking pHT-01 as a carrier and P21 as a promoter, and heterologously expressing the human osteopontin.
2. The bacillus subtilis according to claim 1, wherein the amino acid sequence of the human osteopontin is shown in SEQ ID No. 2.
3. The bacillus subtilis according to claim 1, wherein the nucleotide sequence of the P21 promoter is shown in SEQ ID No. 3.
4. The bacillus subtilis according to claim 1, further comprising the step of promoting secretory expression of human osteopontin with RBS and a signal peptide.
5. The bacillus subtilis according to claim 4, wherein the RBS is selected from one of the nucleotide sequences set forth in SEQ ID nos. 6-23.
6. The bacillus subtilis according to claim 4, wherein the signal peptide is selected from the group consisting of SP YlxW 、SP YwmC 、SP YhdC 、SP YybN 、SP YnfF 、SP YwtD 、SP SpollR 、SP MotB 、SP YxiT 、SP YurL 、SP LytB 、SP Vpr 、SP YbbE 、SP LipA 、SP YddT 、SP Ymol 、SP BdbD One of them.
7. The bacillus subtilis according to claim 1, wherein the host of the bacillus subtilis is b.subtilis G601.
8. A method of constructing a bacillus subtilis according to any one of claims 1 to 7, comprising the steps of:
s1, constructing a P21 promoter, a coding gene of a human osteopontin and an expression element on a pHT-01 vector to obtain an expression vector;
s2, converting the expression vector into a bacillus subtilis host, and screening to obtain the bacillus subtilis.
9. Use of bacillus subtilis according to any one of claims 1 to 7 for the fermentative production of human osteopontin.
10. The use according to claim 9, characterized in that the seed liquid of bacillus subtilis is inoculated into a fermentation medium according to an inoculum size of 2-5% by volume, and is cultivated for 12-96h at 35-37 ℃ and 200-220 rpm.
CN202310592888.1A 2023-05-24 2023-05-24 Bacillus subtilis for efficiently secreting and expressing osteopontin as well as construction method and application thereof Pending CN116536235A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310592888.1A CN116536235A (en) 2023-05-24 2023-05-24 Bacillus subtilis for efficiently secreting and expressing osteopontin as well as construction method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202310592888.1A CN116536235A (en) 2023-05-24 2023-05-24 Bacillus subtilis for efficiently secreting and expressing osteopontin as well as construction method and application thereof

Publications (1)

Publication Number Publication Date
CN116536235A true CN116536235A (en) 2023-08-04

Family

ID=87454163

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202310592888.1A Pending CN116536235A (en) 2023-05-24 2023-05-24 Bacillus subtilis for efficiently secreting and expressing osteopontin as well as construction method and application thereof

Country Status (1)

Country Link
CN (1) CN116536235A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101735314A (en) * 2010-01-28 2010-06-16 上海交通大学 Osteopontin and purpose of protecting liver thereof
CN112695006A (en) * 2021-02-05 2021-04-23 江南大学 Recombinant bacillus subtilis for expressing D-psicose-3-epimerase
CN114606148A (en) * 2022-03-29 2022-06-10 江南大学 Pichia pastoris strain for expressing osteopontin
CN116004701A (en) * 2022-08-10 2023-04-25 江南大学 Pichia pastoris, construction method thereof and application thereof in synthesis of osteopontin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101735314A (en) * 2010-01-28 2010-06-16 上海交通大学 Osteopontin and purpose of protecting liver thereof
CN112695006A (en) * 2021-02-05 2021-04-23 江南大学 Recombinant bacillus subtilis for expressing D-psicose-3-epimerase
CN114606148A (en) * 2022-03-29 2022-06-10 江南大学 Pichia pastoris strain for expressing osteopontin
CN116004701A (en) * 2022-08-10 2023-04-25 江南大学 Pichia pastoris, construction method thereof and application thereof in synthesis of osteopontin

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NCBI REFERENCE SEQUENCE: NP_001035147.1: "osteopontin isoform OPN-a precursor [Homo sapiens]", 《GENBANK》 *
XIANGZONG HAN等: "Transient expression of osteopontin in HEK 293 cells in serum-free culture Author links open overlay panel", 《ENZYME AND MICROBIAL TECHNOLOGY》, vol. 41, no. 1, pages 133 - 140 *
YANG LI等: "A genetic toolkit for efficient production of secretory protein in Bacillus subtilis", 《BIORESOURCE TECHNOLOGY》, vol. 363, pages 3 - 4 *

Similar Documents

Publication Publication Date Title
CN112522173B (en) Engineering bacterium for producing heterologous alkaline protease and construction method thereof
WO2024031921A1 (en) Pichia pastoris with enhanced lactoferrin expression, method for constructing same, and use thereof
CN112210519A (en) Genetically engineered bacterium for secreting acetaldehyde dehydrogenase by using edible fungi
CN116286900A (en) Acetate osmotic enzyme A gene RkAcpa and application thereof
CN111549018B (en) Protease mutant with improved thermal stability as well as coding gene and application thereof
CN115896073A (en) Artificially modified enzyme of high-thermal-stability pepsin and expression application thereof
JP5662363B2 (en) Method for clarifying protein fusion factor (TFP) for secretion of difficult-to-express protein, method for producing protein fusion factor (TFP) library, and method for recombinant production of difficult-to-express protein
CN109022438A (en) A kind of promoter and its application of keratinase heterogenous expression
CN110938614A (en) High-activity β -galactosidase, plasmid for high-throughput screening of same and preparation method thereof
CN116536235A (en) Bacillus subtilis for efficiently secreting and expressing osteopontin as well as construction method and application thereof
CN111363028B (en) Recombinant human type I collagen, expression strain and construction method thereof
CN109997970B (en) Acidic xylanase mutant with improved enzyme activity and heat resistance, and coding gene and application thereof
CN107778365A (en) The recombinant-protein expression that a kind of multiple spot is integrated
CN112175890A (en) Genetically engineered bacterium for secreting alcohol dehydrogenase by using edible fungi
CN113913357B (en) Chassis strain for producing alkaline protease and construction method and application thereof
CN116004701A (en) Pichia pastoris, construction method thereof and application thereof in synthesis of osteopontin
CN115074347A (en) Feed additive containing keratinase mutant and bile acid and application thereof
CN113957028A (en) Bacillus subtilis inactivated by extracellular protease and construction method and application thereof
CN114058606A (en) Application of bacillus licheniformis with deleted xpt gene in production of heterologous protein
CN106632654B (en) Optimized pIFN-gamma peptide chain and application thereof in improving yield and activity of pichia pastoris secretion expression pig IFN-gamma
KR100798894B1 (en) Translational fusion partner for producing recombinant proteins
CN109929849B (en) Optimized pGH gene and protein and application thereof in improving yield and activity of pichia pastoris secretion expression pGH
CN105176952B (en) A kind of alkali protease for improving beans Hectometer degradation efficiencies
CN117568349B (en) Fungal promoter element P22 and application thereof
CN117050163B (en) Pichia pastoris engineering bacteria for secretory expression of recombinant type III collagen and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination